Fifteen Years of Clinical Trials in Huntington’s Disease: A Very Low Clinical Drug Development Success Rate-Reference-Cited by-同舟云学术

Fifteen Years of Clinical Trials in Huntington’s Disease: A Very Low Clinical Drug Development Success Rate

Published:2017-06-30 Issue:2 Volume:6 Page:157-163
ISSN:1879-6397
Container-title:Journal of Huntington's Disease
language:
Short-container-title:JHD

Author:

Travessa André M.¹,Rodrigues Filipe B.¹²³,Mestre Tiago A.⁴,Ferreira Joaquim J.¹²⁵

Affiliation:

1. Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal

2. Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal

3. Huntington’s Disease Centre, Institute of Neurology, University College London, United Kingdom

4. Parkinson’s disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada

5. CNS – Campus Neurológico Sénior, Torres Vedras, Portugal

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Reference27 articles.

1. Huntington disease;Bates;Nat Rev Dis Primers,2015

2. Huntington disease: Natural history, biomarkers and prospects for therapeutics;Ross;Nat Rev Neurol,2014

3. Rodrigues FB , Abreu D , Damásio J , Goncalves N , Correia-Guedes L , Coelho M , et al. Survival, mortality, causes and places of death in a European Huntington’s Disease Prospective Cohort. Mov Disord Clin Pract. 2017. doi: 10.1002/mdc3.12502

4. The incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis;Pringsheim;Mov Disord,2012

5. The prevalence of Huntington’s disease;Rawlins;Neuroepidemiology,2016

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Causal associations of physical activity and leisure sedentary behaviors with age at onset of Huntington's disease: A mendelian randomization study;Parkinsonism & Related Disorders;2024-10

2. Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington’s disease;Archives of Pharmacal Research;2024-05-19

3. 3-Hydroxyanthranilic Acid Delays Paralysis in Caenorhabditis elegans Models of Amyloid-Beta and Polyglutamine Proteotoxicity;Biomolecules;2024-05-18

4. From zinc homeostasis to disease progression: Unveiling the neurodegenerative puzzle;Pharmacological Research;2024-01

5. Recent Challenges of Exosomes as a Novel Carrier in Various Brain Disorders;Exosomes Based Drug Delivery Strategies for Brain Disorders;2024